Abemaciclib sensitizes HPV‐negative cervical cancer to chemotherapy via specifically suppressing CDK4/6‐Rb‐E2F and mTOR pathways

Volume: 35, Issue: 1, Pages: 156 - 164
Published: Jun 10, 2020
Abstract
Cervical cancer is the second most common malignancy in women, and the novel therapeutic treatment is needed. Abemaciclib is a FDA-approved drug for breast cancer treatment. In this work, we identified that abemaciclib has potent anti-cervical cancer activity. We demonstrate that abemaciclib is the most effective drug against human papillomavirus (HPV)-negative cervical cancer cells compared to ribociclib and palbociclib, with its IC50 at...
Paper Details
Title
Abemaciclib sensitizes HPV‐negative cervical cancer to chemotherapy via specifically suppressing CDK4/6‐Rb‐E2F and mTOR pathways
Published Date
Jun 10, 2020
Volume
35
Issue
1
Pages
156 - 164
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.